In the BioHarmony Drug Report Database
Dabigatran
Pradaxa (dabigatran) is a small molecule pharmaceutical. Dabigatran was first approved as Pradaxa on 2008-03-17. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. The pharmaceutical is active against prothrombin. Pradaxa’s patents are valid until 2031-01-20 (FDA).
Trade Name
|
Pradaxa |
|---|---|
Common Name
|
dabigatran |
ChEMBL ID
|
CHEMBL48361 |
Indication
|
replacement arthroplasty, venous thromboembolism |
Drug Class
|
Thrombin inhibitors (argatroban type) |
Image (chem structure or protein)